{"id": "article-499_0", "title": "Chemotherapy Acral Erythema -- Continuing Education Activity", "content": "Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or Burgdorf reaction. It is caused by classic chemotherapeutic agents and newer molecular targeted therapies and characterized by intense, painful erythema of the palms and soles that can progress to vesicles or bullae. This activity discusses the proper identification of the condition and adequate management. This activity highlights the role of the interprofessional team in caring for patients with this condition.", "contents": "Chemotherapy Acral Erythema -- Continuing Education Activity. Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or Burgdorf reaction. It is caused by classic chemotherapeutic agents and newer molecular targeted therapies and characterized by intense, painful erythema of the palms and soles that can progress to vesicles or bullae. This activity discusses the proper identification of the condition and adequate management. This activity highlights the role of the interprofessional team in caring for patients with this condition."}
{"id": "article-499_1", "title": "Chemotherapy Acral Erythema -- Continuing Education Activity", "content": "Objectives: Identify the etiology of palmar-plantar erythrodysesthesia. Describe the exam findings typically seen in patients with palmar-plantar erythrodysesthesia. Describe the potential complications of palmar-plantar erythrodysesthesia. Describe the modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by palmar-plantar erythrodysesthesia. Access free multiple choice questions on this topic.", "contents": "Chemotherapy Acral Erythema -- Continuing Education Activity. Objectives: Identify the etiology of palmar-plantar erythrodysesthesia. Describe the exam findings typically seen in patients with palmar-plantar erythrodysesthesia. Describe the potential complications of palmar-plantar erythrodysesthesia. Describe the modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by palmar-plantar erythrodysesthesia. Access free multiple choice questions on this topic."}
{"id": "article-499_2", "title": "Chemotherapy Acral Erythema -- Introduction", "content": "Acral erythema, also known as Palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, toxic erythema of the palms and soles,\u00a0 hand-foot syndrome (HFS), or\u00a0Burgdorf reaction.\u00a0This is an adverse event caused by many classic chemotherapeutic agents and newer molecular targeted therapies. It is characterized by intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae. [1] [2] [3] .", "contents": "Chemotherapy Acral Erythema -- Introduction. Acral erythema, also known as Palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, toxic erythema of the palms and soles,\u00a0 hand-foot syndrome (HFS), or\u00a0Burgdorf reaction.\u00a0This is an adverse event caused by many classic chemotherapeutic agents and newer molecular targeted therapies. It is characterized by intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae. [1] [2] [3] ."}
{"id": "article-499_3", "title": "Chemotherapy Acral Erythema -- Etiology", "content": "Doxorubicin (most common with pegylated lysosomal preparation), cytarabine, docetaxel, capecitabine, or 5-fluorouracil (mostly infusional regimen) are the most frequently implicated agents [1] [4] .", "contents": "Chemotherapy Acral Erythema -- Etiology. Doxorubicin (most common with pegylated lysosomal preparation), cytarabine, docetaxel, capecitabine, or 5-fluorouracil (mostly infusional regimen) are the most frequently implicated agents [1] [4] ."}
{"id": "article-499_4", "title": "Chemotherapy Acral Erythema -- Etiology", "content": "Other drugs causing acral erythema are bleomycin, cisplatin, cyclophosphamide, daunorubicin, doxifluridine, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ixabepilone, methotrexate, mitotane, paclitaxel, tegafur, thiotepa, and vinorelbine. [5] [6] [7] [8] . It is also postulated that genetic polymorphisms of enzymes involved in the metabolism of some fluoropyrimidines like Capecitabine are the culprit in developing PPE [9]", "contents": "Chemotherapy Acral Erythema -- Etiology. Other drugs causing acral erythema are bleomycin, cisplatin, cyclophosphamide, daunorubicin, doxifluridine, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ixabepilone, methotrexate, mitotane, paclitaxel, tegafur, thiotepa, and vinorelbine. [5] [6] [7] [8] . It is also postulated that genetic polymorphisms of enzymes involved in the metabolism of some fluoropyrimidines like Capecitabine are the culprit in developing PPE [9]"}
{"id": "article-499_5", "title": "Chemotherapy Acral Erythema -- Etiology", "content": "PPE seems to be dose-dependent, and both peak drug concentration and total cumulative dose determine its occurrence.\u00a0Drug formulation and administration schedules that result in sustained serum levels of cytotoxic agents are more frequently associated with acral erythema [10] [11] [1] .", "contents": "Chemotherapy Acral Erythema -- Etiology. PPE seems to be dose-dependent, and both peak drug concentration and total cumulative dose determine its occurrence.\u00a0Drug formulation and administration schedules that result in sustained serum levels of cytotoxic agents are more frequently associated with acral erythema [10] [11] [1] ."}
{"id": "article-499_6", "title": "Chemotherapy Acral Erythema -- Etiology", "content": "Multitargeted tyrosine kinase inhibitors and others that target angiogenesis are associated with hand-foot skin reactions (This is not discussed in the current article). However, clinical and histologic patterns differ from the typical acral erythema that develops with standard cytotoxic agents.", "contents": "Chemotherapy Acral Erythema -- Etiology. Multitargeted tyrosine kinase inhibitors and others that target angiogenesis are associated with hand-foot skin reactions (This is not discussed in the current article). However, clinical and histologic patterns differ from the typical acral erythema that develops with standard cytotoxic agents."}
{"id": "article-499_7", "title": "Chemotherapy Acral Erythema -- Epidemiology", "content": "Overall Incidence of HFS is not well documented. However, the incidence of developing HFS in patients treated with capecitabine is around 60%.", "contents": "Chemotherapy Acral Erythema -- Epidemiology. Overall Incidence of HFS is not well documented. However, the incidence of developing HFS in patients treated with capecitabine is around 60%."}
{"id": "article-499_8", "title": "Chemotherapy Acral Erythema -- Pathophysiology", "content": "Pathogenesis is not very well understood. Researchers think that the accumulation of chemotherapeutic drugs in eccrine glands, which are more numerous in palms and soles, may cause eccrine squamous syringometaplasia (ESS). ESS\u00a0is characterized by metaplasia and focal necrosis of the epithelium of the eccrine duct. ESS is occasionally detected in conjunction with acral erythema, but such occurrences are relatively uncommon.", "contents": "Chemotherapy Acral Erythema -- Pathophysiology. Pathogenesis is not very well understood. Researchers think that the accumulation of chemotherapeutic drugs in eccrine glands, which are more numerous in palms and soles, may cause eccrine squamous syringometaplasia (ESS). ESS\u00a0is characterized by metaplasia and focal necrosis of the epithelium of the eccrine duct. ESS is occasionally detected in conjunction with acral erythema, but such occurrences are relatively uncommon."}
{"id": "article-499_9", "title": "Chemotherapy Acral Erythema -- Pathophysiology", "content": "Data suggests that Capecitabine (fluoropyrimidine) toxicity may be associated with genetic polymorphisms of\u00a0dihydropyrimidine\u00a0dehydrogenase (DPYD) and thymidylate synthase (TYMS), enzymes involved in its metabolism [9] . Data also suggest that palmar skin has a high expression of\u00a0capecitabine-activating enzyme thymidine phosphorylase leading to a high concentration of active component levels [12] .", "contents": "Chemotherapy Acral Erythema -- Pathophysiology. Data suggests that Capecitabine (fluoropyrimidine) toxicity may be associated with genetic polymorphisms of\u00a0dihydropyrimidine\u00a0dehydrogenase (DPYD) and thymidylate synthase (TYMS), enzymes involved in its metabolism [9] . Data also suggest that palmar skin has a high expression of\u00a0capecitabine-activating enzyme thymidine phosphorylase leading to a high concentration of active component levels [12] ."}
{"id": "article-499_10", "title": "Chemotherapy Acral Erythema -- Histopathology", "content": "Histologic changes include dermatitis with necrotic and dyskeratotic keratinocytes, dermal edema, vacuolar degeneration and perivascular lymphocytic infiltrate [5] . However, the biopsy is not usually done promptly for diagnostic purposes.", "contents": "Chemotherapy Acral Erythema -- Histopathology. Histologic changes include dermatitis with necrotic and dyskeratotic keratinocytes, dermal edema, vacuolar degeneration and perivascular lymphocytic infiltrate [5] . However, the biopsy is not usually done promptly for diagnostic purposes."}
{"id": "article-499_11", "title": "Chemotherapy Acral Erythema -- History and Physical", "content": "The condition typically begins with dysesthesias like a tingling sensation in the palms and/or soles and produces symmetric, well-demarcated painful erythema that can\u00a0progress to blistering with desquamation, erosion, and ulceration.\u00a0An especially severe bullous variant that advances to full-thickness epidermal necrosis and sloughing has been reported following\u00a0cytarabine or high-dose intravenous\u00a0methotrexate, particularly in children. Although rare, acral erythema involving the penis and scrotum has been reported.", "contents": "Chemotherapy Acral Erythema -- History and Physical. The condition typically begins with dysesthesias like a tingling sensation in the palms and/or soles and produces symmetric, well-demarcated painful erythema that can\u00a0progress to blistering with desquamation, erosion, and ulceration.\u00a0An especially severe bullous variant that advances to full-thickness epidermal necrosis and sloughing has been reported following\u00a0cytarabine or high-dose intravenous\u00a0methotrexate, particularly in children. Although rare, acral erythema involving the penis and scrotum has been reported."}
{"id": "article-499_12", "title": "Chemotherapy Acral Erythema -- History and Physical", "content": "A presumed variant of acral erythema, called fixed erythrodysesthesia plaque (FEP), is characteristic of intravenous (IV) injections of\u00a0docetaxel. This lesion develops as a fixed, single plaque, proximal to the infusion site, which does not include the palms or soles. It resolves with desquamation and leaves an area of hyperpigmented skin in 5 to 6 weeks. Temporary Loss of fingerprint is seen with capecitabine-associated,\u00a0chronic acral erythema and can cause identification issues.", "contents": "Chemotherapy Acral Erythema -- History and Physical. A presumed variant of acral erythema, called fixed erythrodysesthesia plaque (FEP), is characteristic of intravenous (IV) injections of\u00a0docetaxel. This lesion develops as a fixed, single plaque, proximal to the infusion site, which does not include the palms or soles. It resolves with desquamation and leaves an area of hyperpigmented skin in 5 to 6 weeks. Temporary Loss of fingerprint is seen with capecitabine-associated,\u00a0chronic acral erythema and can cause identification issues."}
{"id": "article-499_13", "title": "Chemotherapy Acral Erythema -- Evaluation", "content": "Painful red swelling of the feet and hands in a patient receiving chemotherapy suggests the\u00a0diagnosis. A high degree of suspicion is the key to diagnosis in patients receiving chemotherapeutic agents. The problem may also occur\u00a0in patients with bone marrow transplants, as the clinical and histologic features may mimic cutaneous manifestations of graft-versus-host disease.", "contents": "Chemotherapy Acral Erythema -- Evaluation. Painful red swelling of the feet and hands in a patient receiving chemotherapy suggests the\u00a0diagnosis. A high degree of suspicion is the key to diagnosis in patients receiving chemotherapeutic agents. The problem may also occur\u00a0in patients with bone marrow transplants, as the clinical and histologic features may mimic cutaneous manifestations of graft-versus-host disease."}
{"id": "article-499_14", "title": "Chemotherapy Acral Erythema -- Evaluation", "content": "Dangerous graft-versus-host disease must be differentiated\u00a0from benign palmar-plantar\u00a0erythrodysesthesia. Patients with graft-versus-host disease will have progression to other body parts whereas PPE will be limited to hands and feet. Serial biopsies every 3 to 5 days may help\u00a0in differentiating the two disorders. [5]", "contents": "Chemotherapy Acral Erythema -- Evaluation. Dangerous graft-versus-host disease must be differentiated\u00a0from benign palmar-plantar\u00a0erythrodysesthesia. Patients with graft-versus-host disease will have progression to other body parts whereas PPE will be limited to hands and feet. Serial biopsies every 3 to 5 days may help\u00a0in differentiating the two disorders. [5]"}
{"id": "article-499_15", "title": "Chemotherapy Acral Erythema -- Treatment / Management", "content": "The mainstay of treatment is the discontinuation of the drug and symptomatic treatment to provide pain relief, decrease edema, and prevent superinfection. Symptomatic treatment includes wound care, alcohol-free emollients, elevation, and pain medication.\u00a0 Healing includes superficial desquamation of affected areas. Often chemotherapy dose intensity modification or reduction is needed if the drug cannot be\u00a0discontinued or substituted\u00a0for\u00a0another cancer drug or cancer treatment. Usually, it resolves within 2 to 4 weeks of drug cessation.", "contents": "Chemotherapy Acral Erythema -- Treatment / Management. The mainstay of treatment is the discontinuation of the drug and symptomatic treatment to provide pain relief, decrease edema, and prevent superinfection. Symptomatic treatment includes wound care, alcohol-free emollients, elevation, and pain medication.\u00a0 Healing includes superficial desquamation of affected areas. Often chemotherapy dose intensity modification or reduction is needed if the drug cannot be\u00a0discontinued or substituted\u00a0for\u00a0another cancer drug or cancer treatment. Usually, it resolves within 2 to 4 weeks of drug cessation."}
{"id": "article-499_16", "title": "Chemotherapy Acral Erythema -- Treatment / Management", "content": "In the case of severe (grade 3) acral erythema, further chemotherapy doses should be reduced to prevent a recurrence. Depending on overall clinical status switching to an alternative regimen may be necessary if the risk of recurrence is thought to be high.", "contents": "Chemotherapy Acral Erythema -- Treatment / Management. In the case of severe (grade 3) acral erythema, further chemotherapy doses should be reduced to prevent a recurrence. Depending on overall clinical status switching to an alternative regimen may be necessary if the risk of recurrence is thought to be high."}
{"id": "article-499_17", "title": "Chemotherapy Acral Erythema -- Differential Diagnosis", "content": "Graft versus host disease (GVHD) Steven johnson syndrome (SJS) Toxic epidermal necrolysis (TEN) Fixed drug eruption", "contents": "Chemotherapy Acral Erythema -- Differential Diagnosis. Graft versus host disease (GVHD) Steven johnson syndrome (SJS) Toxic epidermal necrolysis (TEN) Fixed drug eruption"}
{"id": "article-499_18", "title": "Chemotherapy Acral Erythema -- Treatment Planning", "content": "HFS is dose-related. The treatment for HFS is dose modification or drug interruption. HFS resolves within two to four weeks of discontinuation of the chemotherapy. In patients who are getting capecitabine, topical urea 10% cream can be used for the prevention of HFS from capecitabine. For severe grade 3 HFS, subsequent doses of chemotherapy need to be reduced.", "contents": "Chemotherapy Acral Erythema -- Treatment Planning. HFS is dose-related. The treatment for HFS is dose modification or drug interruption. HFS resolves within two to four weeks of discontinuation of the chemotherapy. In patients who are getting capecitabine, topical urea 10% cream can be used for the prevention of HFS from capecitabine. For severe grade 3 HFS, subsequent doses of chemotherapy need to be reduced."}
{"id": "article-499_19", "title": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management", "content": "Regional cooling using ice packs to wrists and ankles during therapy may help in decreasing the frequency and severity of symptoms by decreasing blood flow [13] [14] . It is usually a well-tolerated prevention strategy.", "contents": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management. Regional cooling using ice packs to wrists and ankles during therapy may help in decreasing the frequency and severity of symptoms by decreasing blood flow [13] [14] . It is usually a well-tolerated prevention strategy."}
{"id": "article-499_20", "title": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management", "content": "Randomized clinical trials using topical urea preparation to\u00a0hands and feet revealed contradictory results depending on the dosage and duration of treatment in patients receiving capecitabine. Further studies need to validate the use to be applied in clinical practice [15] [16] . Studies including meta-analysis conducted using pyridoxine (Vitamin B6) reveal varying results [17] [18] [19]", "contents": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management. Randomized clinical trials using topical urea preparation to\u00a0hands and feet revealed contradictory results depending on the dosage and duration of treatment in patients receiving capecitabine. Further studies need to validate the use to be applied in clinical practice [15] [16] . Studies including meta-analysis conducted using pyridoxine (Vitamin B6) reveal varying results [17] [18] [19]"}
{"id": "article-499_21", "title": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management", "content": "Oral\u00a0 Celecoxib\u00a0200 to 400 mg twice a day for 12 to 18 weeks significantly reduced the risk of grades 2 and 3 HFS (odds ratio 0.37, 95% CI 0.19-0.71) in a meta-analysis of randomized trials [20] . However, celecoxib is known for its potential cardiovascular adverse effects with long-term use and upper gastrointestinal (GI) risk of bleeding. The benefit-to-risk ratio is not favorable for the extensive use of celecoxib for the prevention or treatment of HFS [3] . Studies using systemic corticosteroids in the management of HFS are also not convincing resulting in the need for large randomized clinical trials [21]", "contents": "Chemotherapy Acral Erythema -- Toxicity and Adverse Effect Management. Oral\u00a0 Celecoxib\u00a0200 to 400 mg twice a day for 12 to 18 weeks significantly reduced the risk of grades 2 and 3 HFS (odds ratio 0.37, 95% CI 0.19-0.71) in a meta-analysis of randomized trials [20] . However, celecoxib is known for its potential cardiovascular adverse effects with long-term use and upper gastrointestinal (GI) risk of bleeding. The benefit-to-risk ratio is not favorable for the extensive use of celecoxib for the prevention or treatment of HFS [3] . Studies using systemic corticosteroids in the management of HFS are also not convincing resulting in the need for large randomized clinical trials [21]"}
{"id": "article-499_22", "title": "Chemotherapy Acral Erythema -- Medical Oncology", "content": "Tyrosine kinase inhibitors like sunitinib, sorafenib, bevacizumab which target angiogenesis are also associated with hand-foot skin reaction (HFSR) which is different from HFS from conventional chemotherapy. Studies have shown that HFSR showed an association with tumor response and overall survival. [22] Combined use of chemotherapy and\u00a0 TKI has increased in the recent past. It is crucial to differentiate the side effects between side effects from both the agents to guide the reduction in the appropriate therapy if needed. HFS from cytotoxic chemotherapy causes diffuse erythema and desquamation compared to hyperkeratotic lesions in HSFR.", "contents": "Chemotherapy Acral Erythema -- Medical Oncology. Tyrosine kinase inhibitors like sunitinib, sorafenib, bevacizumab which target angiogenesis are also associated with hand-foot skin reaction (HFSR) which is different from HFS from conventional chemotherapy. Studies have shown that HFSR showed an association with tumor response and overall survival. [22] Combined use of chemotherapy and\u00a0 TKI has increased in the recent past. It is crucial to differentiate the side effects between side effects from both the agents to guide the reduction in the appropriate therapy if needed. HFS from cytotoxic chemotherapy causes diffuse erythema and desquamation compared to hyperkeratotic lesions in HSFR."}
{"id": "article-499_23", "title": "Chemotherapy Acral Erythema -- Staging", "content": "According to the national cancer institute, common terminology criteria for adverse events (NCI CTCAE version 5), Grading of Severity of HFS is classified as follows Grade 1: Minimal skin changes or dermatitis (e.g., erythema or edema) without pain Grade 2 :\u00a0Skin changes (e.g., peeling, blisters, bleeding, or hyperkeratosis) with pain leading to limitation of instrumental activities of daily living (ADL) Grade 3 :\u00a0Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting basic self-care ADL [3]", "contents": "Chemotherapy Acral Erythema -- Staging. According to the national cancer institute, common terminology criteria for adverse events (NCI CTCAE version 5), Grading of Severity of HFS is classified as follows Grade 1: Minimal skin changes or dermatitis (e.g., erythema or edema) without pain Grade 2 :\u00a0Skin changes (e.g., peeling, blisters, bleeding, or hyperkeratosis) with pain leading to limitation of instrumental activities of daily living (ADL) Grade 3 :\u00a0Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting basic self-care ADL [3]"}
{"id": "article-499_24", "title": "Chemotherapy Acral Erythema -- Complications", "content": "PPE can cause a significant impact on a patient's quality of life. There are usually no long-term after-effects; however, palmoplantar keratoderma may develop as a result of long-standing acral erythema.\u00a0Fingerprint loss is reversible after treatment discontinuation.", "contents": "Chemotherapy Acral Erythema -- Complications. PPE can cause a significant impact on a patient's quality of life. There are usually no long-term after-effects; however, palmoplantar keratoderma may develop as a result of long-standing acral erythema.\u00a0Fingerprint loss is reversible after treatment discontinuation."}
{"id": "article-499_25", "title": "Chemotherapy Acral Erythema -- Enhancing Healthcare Team Outcomes", "content": "Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or\u00a0Burgdorf reaction.\u00a0This is an adverse event caused by many classic chemotherapeutic agents and newer molecular targeted therapies. It is an intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae. Healthcare professionals should be familiar with acral erythema while managing patients on chemotherapy. The condition is best managed by an interprofessional team that includes the dermatologist, oncologist, oncology nurse, pharmacist, and primary care provider. Patients and families need to be educated about the condition to be vigilant in monitoring the symptoms. When the condition is diagnosed, depending on the overall clinical condition and severity of symptoms decisions regarding decreasing the dose or discontinuation of treatment need to be made with shared decision making.", "contents": "Chemotherapy Acral Erythema -- Enhancing Healthcare Team Outcomes. Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or\u00a0Burgdorf reaction.\u00a0This is an adverse event caused by many classic chemotherapeutic agents and newer molecular targeted therapies. It is an intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae. Healthcare professionals should be familiar with acral erythema while managing patients on chemotherapy. The condition is best managed by an interprofessional team that includes the dermatologist, oncologist, oncology nurse, pharmacist, and primary care provider. Patients and families need to be educated about the condition to be vigilant in monitoring the symptoms. When the condition is diagnosed, depending on the overall clinical condition and severity of symptoms decisions regarding decreasing the dose or discontinuation of treatment need to be made with shared decision making."}
{"id": "article-499_26", "title": "Chemotherapy Acral Erythema -- Enhancing Healthcare Team Outcomes", "content": "Regional cooling with ice packs around wrists and ankles is a well-tolerated strategy with no side effects and should be tried. There is a need for large randomized controlled trials to formulate appropriate management options to treat the condition effectively. Overall, the quality of life is poor if the condition is not adequately treated [Level V] [5] .", "contents": "Chemotherapy Acral Erythema -- Enhancing Healthcare Team Outcomes. Regional cooling with ice packs around wrists and ankles is a well-tolerated strategy with no side effects and should be tried. There is a need for large randomized controlled trials to formulate appropriate management options to treat the condition effectively. Overall, the quality of life is poor if the condition is not adequately treated [Level V] [5] ."}
{"id": "article-499_27", "title": "Chemotherapy Acral Erythema -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Chemotherapy Acral Erythema -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}